Shifting the limits of resuscitation with “CIRD Controlled Integrated Resuscitation Device” (CIRDinnova)
Project summary
Only 3% of the patients survive out-of-hospital resuscitation, and only 18% survive in-hospital resuscitation. In order to increase survival, a therapy was developed named CARL: Controlled Automated Reperfusion of the whoLe body. In this project, the technology is further developed from TRL 7 towards TRL 9.
Impact
Bringing the CARL therapy towards the market, resulting in improved survival rates and better quality of life for survivors after resuscitation.
More detailed information
Principal Investigator:
Dinis Dos Reis Miranda
Role Erasmus MC:
Partner
Department:
Project website:
Not available
Funding Agency:
Horizon 2020 Fast Track to Innovation Pilot
